Ginkgo Bioworks Holdings, Inc. (DNA)

Market Cap	631.56M
Revenue (ttm)	237.42M
Net Income (ttm)	-472.08M
Shares Out	58.53M
EPS (ttm)	-8.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	987,308
Open	11.09
Previous Close	11.07
Day's Range	10.73 - 11.54
52-Week Range	5.00 - 16.85
Beta	1.49
Analysts	Sell
Price Target	9.67 (-10.38%)
Earnings Date	Aug 7, 2025

About DNA

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 834
• Stock Exchange: NYSE
• Ticker Symbol: DNA
• Website: https://www.ginkgo.bio

Financial Performance

In 2024, Ginkgo Bioworks Holdings's revenue was $227.04 million, a decrease of -9.71% compared to the previous year's $251.46 million. Losses were -$547.03 million, -38.73% less than in 2023.

Analyst Summary

According to 3 analysts, the average rating for DNA stock is "Sell." The 12-month stock price target is $9.67, which is a decrease of -10.38% from the latest price.

Price Target

$9.67

(-10.38% downside)

Analyst Consensus: Sell